James Wilson turns to old mentor for gene therapy startup's star-studded $115M launch round
Gene therapies have long held promise for rare diseases — many of which are monogenic — as an elegant cure that corrects the singular underlying genetic defects. The execution, though, has been anything but elegant, spawning headaches about safety issues and delivery methods.
Penn professor James Wilson knows the roller coaster ride all too well. And as the field gains steam following the historic approval of the first gene therapy with several more lined up at the FDA, he is teaming up with a rare disease expert and an industry vet to develop new therapeutics using a technology that he’s helped perfect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.